A comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations and bispecific antibodies.

The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expansion initiatives across North America, Europe, and Asia-Pacific regions.

Xencor reported strong Q2 2025 financial performance with revenue of $43.6 million, beating estimates by 93%. The company advanced several clinical programs in oncology and autoimmune disorders and received a significant milestone payment from Incyte.

The global Ultomiris drug market is expected to grow from USD 4.16 Billion in 2024 to USD 64.12 Billion by 2034, with a robust 31.52% CAGR, driven by increasing demand for long-acting treatments for rare disorders like PNH and gMG.

Xencor shares surged 10.5% after the company announced a secondary stock offering to raise $175 million. The company plans to use the funds to support its pipeline development. However, earnings and revenue expectations for the upcoming quarter are negative, which may impact the stock's future performance.

In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 2 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.4, a high estimate of $40.00, and a low estimate of $31.00. A decline of 17.29% from the prior average price target is evident in the current average. Investigating Analyst Ratings: An Elaborate Study A clear picture of Xencor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Sean McCutcheon Raymond James Lowers Strong Buy $40.00 $58.00 Etzer Darout BMO Capital Lowers Outperform $32.00 $34.00 Gregory Renza RBC Capital Lowers Outperform $31.00 $32.00 David Nierengarten Wedbush Raises Outperform $36.00 $34.00 Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xencor. This insight gives a snapshot of analysts' perspectives on the current state of the ...Full story available on Benzinga.com

6 analysts have shared their evaluations of Xencor (NASDAQ:XNCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Xencor, presenting an average target of $33.0, a high estimate of $38.00, and a low estimate of $24.00. A decline of 17.91% from the prior average price target is evident in the current average. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Xencor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Nierengarten Wedbush Raises Outperform $36.00 $34.00 Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Edward Tenthoff Piper Sandler Lowers Neutral $24.00 $37.00 Gregory Renza RBC Capital Maintains Outperform $32.00 - Etzer Darout BMO Capital Lowers Outperform $34.00 $38.00 David Nierengarten Wedbush Lowers Outperform $34.00 $36.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xencor. This information provides a snapshot of ...Full story available on Benzinga.com

Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

In the preceding three months, 6 analysts have released ratings for Xencor (NASDAQ:XNCR), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 3 1 0 0 3M Ago 1 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.33, along with a high estimate of $50.00 and a low estimate of $24.00. Experiencing a 21.84% decline, the current average is now lower than the previous average price target of $45.20. Deciphering Analyst Ratings: An In-Depth Analysis The standing of Xencor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Edward Tenthoff Piper Sandler Lowers Neutral $24.00 $37.00 Gregory Renza RBC Capital Maintains Outperform $32.00 - Etzer Darout BMO Capital Lowers Outperform $34.00 $38.00 David Nierengarten Wedbush Lowers Outperform $34.00 $36.00 Mara Goldstein Mizuho Lowers Buy $50.00 $59.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xencor. This information provides a snapshot of how analysts perceive the current state of ...Full story available on Benzinga.com

Ratings for Xencor (NASDAQ:XNCR) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 3 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated Xencor and provided 12-month price targets. The average target is $37.5, accompanied by a high estimate of $50.00 and a low estimate of $32.00. Highlighting a 15.41% decrease, the current average has fallen from the previous average price target of $44.33. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive Xencor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gregory Renza RBC Capital Maintains Outperform $32.00 - Etzer Darout BMO Capital Lowers Outperform $34.00 $38.00 David Nierengarten Wedbush Lowers Outperform $34.00 $36.00 Mara Goldstein Mizuho Lowers Buy $50.00 $59.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xencor. This information provides a snapshot of how analysts ...Full story available on Benzinga.com